These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 4213265)

  • 81. In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa.
    Watanakunakorn C
    Antimicrob Agents Chemother; 1983 Aug; 24(2):305-6. PubMed ID: 6314890
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [[Fundamental and clinical studies of amikacin (BB-K8) in surgical field (author's transl)]?].
    Shibata K; Fugii M; Shinagawa N; Suzuki Y; Muramatsu
    Jpn J Antibiot; 1974 Oct; 27(5):625-32. PubMed ID: 4218270
    [No Abstract]   [Full Text] [Related]  

  • 83. Antibiotic resistance patterns during aminoglycoside restriction.
    Young EJ; Sewell CM; Koza MA; Clarridge JE
    Am J Med Sci; 1985 Dec; 290(6):223-7. PubMed ID: 3936358
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Mezlocillin: a new acyl ureidopenicillin. Antimicrobial activity and combination effects with four aminoglycoside antibiotics.
    Schassan HH; Koperski K; Scherf H
    Chemotherapy; 1978; 24(3):134-42. PubMed ID: 95925
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Gentamicin and tobramycin--an in vitro comparison using 1400 clinical isolates.
    Forgan-Smith WR; Andrew JH; McSweeney RJ
    Pathology; 1976 Jul; 8(3):195-9. PubMed ID: 826868
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [The role of aminoglycoside--modifying enzymes in resistance of Gram-negative rods].
    Jakoniuk P; Wieczorek P; Sacha PT; Zalewska M; Leszczyńska K
    Med Dosw Mikrobiol; 2006; 58(4):363-70. PubMed ID: 17642314
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Review of epidemic aminoglycoside resistance worldwide.
    Mayer KH
    Am J Med; 1986 Jun; 80(6B):56-64. PubMed ID: 3089005
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Comparative in vitro activity of three aminoglycosidic antibiotics: BB-K8, kanamycin, and gentamicin.
    Yu PK; Washington JA
    Antimicrob Agents Chemother; 1973 Aug; 4(2):133-9. PubMed ID: 4208506
    [TBL] [Abstract][Full Text] [Related]  

  • 89. In vitro aminoglycoside resistance of gram-negative bacilli and staphylococci isolated from blood in Sweden 1980-1984.
    Bengtsson S; Bernander S; Brorson JE; Dornbusch K; Forsgren A; Hallander H; Henning C; Holm S; Malmborg AS; Nilsson L
    Scand J Infect Dis; 1986; 18(3):257-63. PubMed ID: 3738436
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Aminoglycoside-resistant enterococci.
    Basker MJ; Slocombe B; Sutherland R
    J Clin Pathol; 1977 Apr; 30(4):375-80. PubMed ID: 404337
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Prevalence and mechanisms of aminoglycoside resistance. A ten-year study.
    Phillips I; King A; Shannon K
    Am J Med; 1986 Jun; 80(6B):48-55. PubMed ID: 3728534
    [TBL] [Abstract][Full Text] [Related]  

  • 92. In vitro studies with Sch 21420 and Sch 22591: activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci.
    Sanders CC; Sanders WE; Goering RV
    Antimicrob Agents Chemother; 1978 Aug; 14(2):178-84. PubMed ID: 697346
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Properties of an R plasmid in Pseudomonas aeruginosa producing amikacin (BB-K8), butirosin, kanamycin, tobramycin, and sisomicin resistance.
    Jacoby GA
    Antimicrob Agents Chemother; 1974 Dec; 6(6):807-10. PubMed ID: 4217586
    [TBL] [Abstract][Full Text] [Related]  

  • 94. In vitro studies with netilmicin compared with amikacin, gentamicin, and tobramycin.
    Dhawan V; Marso E; Martin WJ; Young LS
    Antimicrob Agents Chemother; 1977 Jan; 11(1):64-73. PubMed ID: 836015
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comparative in vitro activity of tobramycin, gentamicin, kanamycin, colistin, carbenicillin, and ticarcillin and clinical isolates of Pseudomonas aeruginosa: epidemiological and therapeutic implications.
    Dulong de Rosnay HL; Grimont PA; Dessaut B; Lesgouarres MT
    J Infect Dis; 1976 Aug; 134 Suppl():S50-6. PubMed ID: 823279
    [TBL] [Abstract][Full Text] [Related]  

  • 96. 1-N HAPA gentamicin B, a new aminoglycoside active against gentamicin resistant isolates--activity compared to other aminoglycosides.
    Neu HC; Fu KP
    J Antibiot (Tokyo); 1978 May; 31(5):385-93. PubMed ID: 27494
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa.
    Kluge RM; Standiford HC; Tatem B; Young VM; Greene WH; Schimpff SC; Calia FM; Hornick RB
    Antimicrob Agents Chemother; 1974 Oct; 6(4):442-6. PubMed ID: 4157342
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates.
    Jones RN; Barry AL; Fuchs PC; Gavan TL; Sommers HM; Gerlach EH
    Antimicrob Agents Chemother; 1979 Dec; 16(6):823-8. PubMed ID: 533262
    [TBL] [Abstract][Full Text] [Related]  

  • 99. In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.
    Angehrn P
    Eur J Clin Microbiol; 1983 Oct; 2(5):489-95. PubMed ID: 6315424
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Long-term amikacin use. Effects on aminoglycoside susceptibility patterns of gram-negative bacilli.
    Moody MM; de Jongh CA; Schimpff SC; Tillman GL
    JAMA; 1982 Sep; 248(10):1199-202. PubMed ID: 6809965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.